STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Company

Lyell Immunopharma, Inc.

Filed

March 9, 2026

Period of Report

March 6, 2026

Accession Number

0001012975-26-000235